The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease

Kidney International

Volumn 86, Issue 2, 2014, Pages 407-413

  Taal, Maarten W ^a   Thurston, Victoria ^a   McIntyre, Natasha J ^a   Fluck, Richard J ^a   McIntyre, Christopher W ^a,b  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

FGF23; parathyroid hormone; phosphate; Vitamin D

Indexed keywords

CALCIFEDIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; URIC ACID; FIBROBLAST GROWTH FACTOR; PTH PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOFLUORESCENCE; BODY MASS; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; NUTRITIONAL DEFICIENCY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BALANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; SENSITIVITY ANALYSIS; SEX RATIO; SKINE AUTOFLUORESCENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D INSUFFICIENCY; VITAMIN SUPPLEMENTATION; WAIST HIP RATIO; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE COURSE; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CALCIFEDIOL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D DEFICIENCY;

EID: 84905499479     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.537     Document Type: Article

References (28)

1. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747.
2. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314: 409-414.
3. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
4. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008.
5. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427-1435.
6. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
7. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
8. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
9. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966.
10. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922.
11. Arnlov J, Carlsson AC, Sundstrom J et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013; 8: 781-786.
12. Lundberg S, Qureshi AR, Olivecrona S et al. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 2012; 7: 727-734.
13. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
14. Westerberg PA, Linde T, Wikstrom B et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3202-3207.
15. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315.
16. Sutton-Tyrrell K, Najjar SS, Boudreau RM et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005; 111: 3384-3390.
17. Desjardins L, Liabeuf S, Renard C et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012; 23: 2017-2025.
18. Houston J, Smith K, Isakova T et al. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. J Ren Nutr 2013; 23: 12-20.
19. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
20. de Lusignan S, Gallagher H, Jones S et al. Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results. Kidney Int 2013; 84: 609-620.
21. McIntyre NJ, Fluck RJ, McIntyre CW et al. Risk profile in chronic kidney disease stage 3: older vs. younger patients. Nephron Clin Pract 2011; 119: c269-c276.
22. McIntyre NJ, Fluck RJ, McIntyre CW et al. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3 Clin J Am Soc Nephrol 2011; 6: 2356-2363.
23. The National Institute for Health and Clinical Excellence. Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. www.nice.org.uk/ nicemedia/pdf/ CG073NICEGuideline.pdf. 2008 15/09/10.
24. The World Health Organisation and the International Diabetes Federation. The Definition and Diagnosis of Diabetes Mellitus and Intermediate Glycaemia. WHO Press 2006.
25. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
26. McIntyre NJ, Fluck RJ, McIntyre CW et al. Determinants of arterial stiffness in chronic kidney disease stage 3. PLoS One 2013; 8: e55444.
27. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ 2010; 340: 142-147.
28. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 4957-4960.